Pulmonary Fibrosis News
56.5K views | +1 today
Follow
 
Scooped by Bill Vick
onto Pulmonary Fibrosis News
Scoop.it!

Strategies for Reducing or Preventing the Generation of Oxidative Stress or why I take CoQ10

Strategies for Reducing or Preventing the Generation of Oxidative Stress or why I take CoQ10 | Pulmonary Fibrosis News | Scoop.it

It is believed that the oxidative damage is the major senescence process, and the mitochondria are the major source of endogenous reactive oxygen species formation while UVR, air pollution, and smoking are the main exogenous sources. Overall, antioxidant defense seems to be in approximate balance with oxygen-derived species generation in vivo. There appears to be no great reserve of antioxidant defenses in mammals, perhaps because some oxygen-derived species perform useful metabolite roles. Certain compounds or strategies cause an activation of mitochondrial oxygen consumption and promote increased formation of ROS formation. 

more...
No comment yet.
Pulmonary Fibrosis News
A call to warriors in the fight against IPF
Curated by Bill Vick
Your new post is loading...
Your new post is loading...
Scooped by Bill Vick
Scoop.it!

Genentech Helps Pulmonary Fibrosis Foundation Programs

Genentech Helps Pulmonary Fibrosis Foundation Programs | Pulmonary Fibrosis News | Scoop.it
Learn more about Genentech helping Pulmonary Fibrosis Foundation programs.
more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Doctors understand patients' IPF concerns

Doctors understand patients' IPF concerns | Pulmonary Fibrosis News | Scoop.it
“A new survey of more than 400 pulmonologists from 10 countries found that 88% of pulmonologists believe a delay in the diagnosis of idiopathic pulmonary fibrosis (IPF) negatively impacts patients.”
Bill Vick's insight:
The survey showed that slowing disease progression is considered the biggest benefit of initiating treatment when IPF is first diagnosed (81%) and pulmonologists’ primary reason for selecting a pharmaceutical treatment for IPF (78%). Improving patient quality of life was the second highest motivation for pulmonologists when selecting an IPF treatment (63%). In addition to asking pulmonologists about their approaches to treatment, the survey asked participants to consider IPF from the patient’s perspective, including impact of the disease. When asked what was most important for an IPF patient to understand in terms of knowing how IPF will affect them, 77% of pulmonologists stated, “knowing what treatment options are available for IPF," and 68% said “knowing that IPF is unpredictable and that their condition could change suddenly and unexpectedly
more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Healthy Living: Hope for IPF - (Video)

Healthy Living: Hope for IPF - (Video) | Pulmonary Fibrosis News | Scoop.it
For decades, doctors had little hope for patients with idiopathic pulmonary fibrosis or IPF, a disease that scars the lungs and makes it hard to breathe.
Bill Vick's insight:

For decades, doctors had little hope for patients with idiopathic pulmonary fibrosis or IPF, a disease that scars the lungs and makes it hard to breathe.

Now, for the first time, doctors say new drugs can buy patients some time.

Michelle Dunaway has the details in tonight’s Healthy Living.

The American Lung Association estimates that 140,000 people are living with IPF.

Fifty-thousand new cases are diagnosed every year.

more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

New Treatments for Deadly Idiopathic Pulmonary Fibrosis - WSJ

New Treatments for Deadly Idiopathic Pulmonary Fibrosis - WSJ | Pulmonary Fibrosis News | Scoop.it
Two recently approved drugs—Esbrit and Ofev—halt the advance of idiopathic pulmonary fibrosis as diagnoses are on the rise.
Bill Vick's insight:

Researchers suspect the disease is linked to an exaggerated or uncontrolled healing response, possibly triggered by the immune system, which produces excessive scar tissue in the lungs and thickens the walls of the alveoli, or air sacs. Smoking is one of the most recognized risks. Exposure to wood or metal dust, viral or bacterial lung infections, and a history of acid reflux disease are possible culprits.

more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Vera Goulet - PULMONARY FIBROSIS... ASK ME ABOUT IT!!! ♥ ♥

Robert Goulet was one of the over 40,000 people who die each year from IPF.

Bill Vick's insight:

There is no known cause, no FDA-approved treatment and no cure for PF.The damage caused from the lung scarring cannot be reversed. In addition, disease progression cannot be predicted or halted. Current experimental treatments are aimed at slowing or halting disease progression. Approximately 200,000 people in the United States have Pulmonary Fibrosis, and prevalence is on the rise with an estimated 48,000 new cases developing each year. An estimated 40,000 people die each year from PF – one every 13 minutes (approximately the same number that die annually from breast cancer).Prevalence has increased 150% since 2001, when it was thought that only 50,000 were affected. PF can strike anyone, but the disease tends to affect men more than women and usually occurs between the ages of 50 and 70. A study by the American Lung Association (ALA) indicates that mortality rate from PF has increased significantly, especially in women, and is predicted to continue to rise.

more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Recruiters Toolkit: 46 Chrome Extensions for Sourcing

Recruiters Toolkit: 46 Chrome Extensions for Sourcing | Pulmonary Fibrosis News | Scoop.it
Chrome extensions are a wonderful addition to a recruiters toolkit. Here are 46 of the best extensions for Recruiting and Sourcing Professionals.
Bill Vick's insight:

Finding the right mix of extensions will absolutely give you some time back, and make sourcing, recruiting, employment branding and marketing quite a bit easier.  Extensions definitely have more impact than what the nay-sayers have to say about “those extensions.”  It’s possible extensions created trauma for folks stuck in their ways. Sometimes, it’s easier to use a quick tool you know produces 90%+ of the same results versus using “tried and true” best practices, it’s a basic prioritization decision (disclaimer: mad respect to industry leaders, but sometimes old-school logic seems, well, not logical).

 
more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Idiopathic Pulmonary Fibrosis - An Introduction to #IPF

Idiopathic Pulmonary Fibrosis - An Introduction to #IPF | Pulmonary Fibrosis News | Scoop.it

Shortness of breath. A lingering dry cough. Getting tired easily. 

Taken alone or together, these symptoms can be associated with multiple conditions. Since they may seem fairly innocuous at first, they are often ignored or dismissed. Someone experiencing them might wait months or even years before seeing his or her doctor about them. 

Bill Vick's insight:

According to Steven Nathan, MD, (medical director, Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital in Falls Church, Va.), who has published extensively on the topic, even lung specialists could miss IPF due to its similarity to other lung diseases.

The medical community has not yet determined why some people develop IPF, while others with similar risk factors do not. The genetic factors in the disease are not well understood, but some scientists believe that in some cases IPF may be the result of an interaction between one's genetic inclination for developing the disease and his or her environment.6According to Dr. Nathan, the more noxious fumes a person is exposed to, the higher the chance that he or she may develop IPF.

more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Idiopathic Pulmonary Fibrosis News - developments in treatment of #IPF

Idiopathic Pulmonary Fibrosis News - developments in treatment of #IPF | Pulmonary Fibrosis News | Scoop.it

This is really for Physicians but the faculty is amongst the very best of the best ILD Pulmonary Medical Doctors and the publications is on target.

 

 

Faculty Listing:

Harold R. Collard, MD
Associate Professor of Medicine
Director, Interstitial Lung Disease Program
University of California San Francisco
San Francisco, California

Kevin R. Flaherty, MD, MS
Professor of Medicine
Medical Director
Idiopathic Pulmonary Fibrosis Foundation Clinical Care Site
University of Michigan Health System
Ann Arbor, Michigan

Steven D. Nathan, MD
Medical Director
Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Falls Church, Virginia

Bill Vick's insight:

Idiopathic Pulmonary Fibrosis #IPF: Coverage From Denver


Target Audience:
The target learning audience is a national audience of pulmonologists, primary care physicians, and other clinicians with an interest in idiopathic pulmonary fibrosis (IPF).

Program Overview:
This newsletter activity highlights the latest developments in the treatment of IPF presented at an international conference of pulmonologists held in Denver, Colorado in May 2015.


Learning Objectives:

Review the latest data on treatments for idiopathic pulmonary fibrosis (IPF)Discuss how therapeutic advances in IPF are guiding research into improved care


more...
Vonda Alexander's curator insight, August 1, 2015 10:36 PM

Idiopathic Pulmonary Fibrosis #IPF: Coverage From Denver

 

Target Audience:
The target learning audience is a national audience of pulmonologists, primary care physicians, and other clinicians with an interest in idiopathic pulmonary fibrosis (IPF).

Program Overview:
This newsletter activity highlights the latest developments in the treatment of IPF presented at an international conference of pulmonologists held in Denver, Colorado in May 2015.

 

Learning Objectives:

Review the latest data on treatments for idiopathic pulmonary fibrosis (IPF)Discuss how therapeutic advances in IPF are guiding research into improved care

 

Carol Stanton's curator insight, August 7, 2015 7:27 AM

Idiopathic Pulmonary Fibrosis #IPF: Coverage From Denver


Target Audience:
The target learning audience is a national audience of pulmonologists, primary care physicians, and other clinicians with an interest in idiopathic pulmonary fibrosis (IPF).

Program Overview:
This newsletter activity highlights the latest developments in the treatment of IPF presented at an international conference of pulmonologists held in Denver, Colorado in May 2015.


Learning Objectives:

Review the latest data on treatments for idiopathic pulmonary fibrosis (IPF)Discuss how therapeutic advances in IPF are guiding research into improved care


Scooped by Bill Vick
Scoop.it!

HR Insights Blog | The Changing Landscape of Online Recruiting

HR Insights Blog | The Changing Landscape of Online Recruiting | Pulmonary Fibrosis News | Scoop.it
Recruiters can no longer rely on the ‘free’ social solutions on the leading aggregate sites and are being asked to purchase pay-per-click search listings, and/or to access prospective candidates and post jobs. Numerous vendors are now selling full-service technology solutions to push jobs out to free and paid sites (where there is no guarantee another site will accept/post the listing).
Bill Vick's insight:

What has NOT changed in online recruiting is the mission of the employer to get prospective candidates to the company’s website as quickly and directly as possible. This is primarily accomplished through search engine optimization and marketing—where many online job seekers start. Only, in this space, the direct common issue Wagner encounters with her clients is that employers are competing with the job boards/aggregators (and competing employers) for PAGE 1 space.

more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis.

Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. | Pulmonary Fibrosis News | Scoop.it

This study sought to evaluate the long-term effects of a 12-week ET program on clinical outcomes in IPF patients.

Bill Vick's insight:

The bottom line of an Exercise Training program in effecting the outcome of #IPF according to a NIH sponsored trial is " We suggest including ET as a long-term continued treatment and as a core component of pulmonary rehabilitation programs for IPF patients."


In other words move, move, move...

more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

New Guidelines for the Treatment of Idiopathic Pulmonary Fibrosis Released by Leading Respiratory Societies

New Guidelines for the Treatment of Idiopathic Pulmonary Fibrosis Released by Leading Respiratory Societies | Pulmonary Fibrosis News | Scoop.it
Updated guidelines on the treatment of idiopathic pulmonary fibrosis (IPF) have been released by an international group of leading respiratory societies, The new guidelines, issued by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association, were published in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.
Bill Vick's insight:

• The recommendation against the use of the following agents for the treatment of IPF is strong:
o Anticoagulation (warfarin)
o Imatinib, a selective tyrosine kinase inhibitor against platelet-derived growth factor (PDGF) receptors 
o Combination prednisone, azathioprine, and N-acetylcysteine
o Selective endothelin receptor antagonist (ambrisentan)

• The recommendation for the use of the following agents for the treatment of IPF is conditional:
o Nintedanib, a tyrosine kinase inhibitor that targets multiple tyrosine kinases, including vascular endothelial growth factor, fibroblast growth factor, and PDGF receptors
o Pirfenidone

• The recommendation against the use of the following agents for the treatment of IPF is conditional:
o Phosphodiesterase-5 inhibitor (sildenafil)
o Dual endothelin receptor antagonists (macitentan, bosentan)

more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Idiopathic Pulmonary Fibrosis: Novel Treatment Promising

Idiopathic Pulmonary Fibrosis: Novel Treatment Promising | Pulmonary Fibrosis News | Scoop.it
Severely ill patients with acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) may benefit from treatments that reduce autoantibodies, according to a pilot trial. Specifically, therapeutic plasma exchange (TPE) and rituximab rapidly reduced circulating autoantibodies in quickly progressing patients. The investigators argue that the findings justify clinical trials of autoantibody-targeted therapies in this patient population.
Bill Vick's insight:

Results suggest that what was once considered an untreatable syndrome in IPF may respond to specific autoantibody-targeted therapies.

more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Personalized medicine in idiopathic pulmonary fibrosis: fac... : Current Opinion in Pulmonary Medicine

Purpose of review: In this article, we summarize and discuss the most recent literature on personalized medicine in idiopathic pulmonary fibrosis (IPF), a chronic progressive and almost invariably lethal disease of unknown cause.
Bill Vick's insight:
Clinical management of IPF is unsatisfactory because of limited availability of truly effective therapies, lack of accurate predictors of disease behavior and absence of simple short-term measures of therapeutic response. A number of putative biomarkers have been identified in patients with IPF, although none has been validated to the standard necessary for their use in either therapeutic trials.
more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

What are the types of Lung Fibrosis ?

“What are the types of Lung Fibrosis ? . . . Pulmonary fibrosis is one of a family of related diseases ucalled interstitial lung diseases that can. When the scar forms, ...”
Bill Vick's insight:
Pulmonary fibrosis is one of a family of related diseases ucalled interstitial lung diseases that can. When the scar forms, ...”
more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

The NIH has awarded $3.5 million to develop new techniques

The NIH has awarded $3.5 million to develop new techniques | Pulmonary Fibrosis News | Scoop.it

The Transformative Research Award promotes cross-cutting, interdisciplinary approaches and is open to individuals and teams of investigators who propose research that could potentially create or challenge existing paradigms.

Bill Vick's insight:

The National Institutes of Health (NIH) has announced a $3.5 million Transformative Research Award to Thomas Barker, an associate professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. The five-year grant will support research into new approaches for tracking and treating pulmonary fibrosis, a disease that claims 40,000 lives per year.

more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Pulmonary Fibrosis Foundation Announces 2015 Research Fund To Cure Pulmonary Fibrosis Award Recipients

Pulmonary Fibrosis Foundation Announces 2015 Research Fund To Cure Pulmonary Fibrosis Award Recipients | Pulmonary Fibrosis News | Scoop.it

The Pulmonary Fibrosis Foundation Announces 2015 Research Fund To Cure Pulmonary Fibrosis Award Recipients

Bill Vick's insight:

The Pulmonary Fibrosis Foundation (PFF) announced today the recipients of the 2015 Established Investigator and Junior Investigator Awards. The Established Investigator and Junior Investigator Awards are funded by the PFF’s Research Fund to Cure Pulmonary Fibrosis and are intended to support advances in the scientific understanding and treatment of pulmonary fibrosis (PF).

more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Effect of acid suppression therapy on gastroesophageal reflux and cough in IPF

Effect of acid suppression therapy on gastroesophageal reflux and cough in IPF | Pulmonary Fibrosis News | Scoop.it

The finding that non-acid reflux is increased following the use of acid suppression therapies cautions against the widespread use of acid suppression in patients with Idiopathic Pulmonary Fibrosis

Bill Vick's insight:

Chronic cough affects more than 70 percent of patients with Idiopathic Pulmonary Fibrosis and causes significant morbidity. Gastroesophageal reflux is the cause of some cases of chronic cough; and also has a postulated role in the aetiology of Idiopathic Pulmonary Fibrosis. A high prevalence of acid; and more recently non-acid, reflux has been observed in Idiopathic Pulmonary Fibrosis cohorts. Therefore, gastroesophageal reflux may be implicated in the pathogenesis of cough in Idiopathic Pulmonary Fibrosis.

more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Does the Vagus Nerve Regulate Pulmonary Fibrosis #PF Progression?

Does the Vagus Nerve Regulate Pulmonary Fibrosis #PF Progression? | Pulmonary Fibrosis News | Scoop.it

The role of inflammation in IPF is controversial. Fibrosis may occur without inflammation and anti-inflammatory or immunosuppressive therapy has not been effective for IPF.

Bill Vick's insight:

The hypothesis was tested by comparing the extent and severity of fibrosis in lungs with and without vagal innervation in unilaterally vagotomized mice. Although the role of sundry cellular and immune modulator factors has been intensely investigated, the pathogenesis of PF remains idiopathic in most cases.


Recently, the vagus nerve has been found to play an important role in neuro-immune interaction and is involved in a variety of pulmonary disease processes. However, its relation to PF is not known. Many reports suggest that the vagus nerve may be directly or indirectly involved in fibrogenic processes. 

more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis - The American Thoracic Society for #IPF

Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis - The American Thoracic Society for #IPF | Pulmonary Fibrosis News | Scoop.it

A comprehensive study and overview of treatment options for IPF discussing both the pro's and con's of various drugs including Esbriet and Ofev.

Bill Vick's insight:

The bottom line is both current drugs used to slow down the progression of IPF (Esbriet and Ofev) are recommended along with strong advice for anti acid (GERD) treatment. Discusses many issues including drug combinations, transplants, etc. Somewhat technical but a must read for patients and caregivers wanting to understand current thoughts on treating IPF.

more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Biological Fluke Breathes New Life into Lung Transplants

Biological Fluke Breathes New Life into Lung Transplants | Pulmonary Fibrosis News | Scoop.it
More than 300,000 Americans die of lung disease each year, making it the nation's third-leading killer. Now, however, there's new hope for the people who desperately need lung transplants, based on a biological fluke.
more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Special Report: Do Stem Cell Telomeres Drive Most Idiopathic Pulmonary Fibrosis Cases?

Special Report: Do Stem Cell Telomeres Drive Most Idiopathic Pulmonary Fibrosis Cases? | Pulmonary Fibrosis News | Scoop.it
Dysfunctional telomeres—molecular caps that keep chromosomes from unraveling like shoelace nubs—may be critical to idiopathic pulmonary fibrosis (IPF), which kills in two to three years.
Bill Vick's insight:

For decades it was thought IPF was caused by inflammation, immune cells run amok. But in recent years, papers by many teams, includingKaminski’s, have found inflammation to be secondary. Those papers indicate inflammatory cells are just rushing to the scene of a mysterious epithelial cell injury, one that first prompts alveolar epithelial cells to undergo hyperplasia—then slowly die. The prolonged death process signals fibroblasts, immune cells, and other scarring cells to move in, and deliver the last in a series of lethal blows to the lung.

 

IPF is likely caused by aberrant wound healing, not inflammation, many papers found.

more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Cigarette Smoking Liked To Interstitial Lung Diseases, IPF

Cigarette Smoking Liked To Interstitial Lung Diseases, IPF | Pulmonary Fibrosis News | Scoop.it

According to the authors, cigarette smoking leads to an exaggerated accumulation of inflammatory cells in the small airways and interstitium (the tissue and space surrounding the air sacs of the lungs). Smoking also triggers the production of transforming growth factor (TGF)-beta 1, a molecule that plays a central role in the development of lung fibrosis.

Bill Vick's insight:

A new study recently published in the journal Respirology reviewed the growing evidence of a link between cigarette smokingand the development of interstitial lung diseases (ILD) including idiopathic pulmonary fibrosis (IPF). 

more...
Carol Stanton's curator insight, August 7, 2015 7:28 AM

A new study recently published in the journal Respirology reviewed the growing evidence of a link between cigarette smokingand the development of interstitial lung diseases (ILD) including idiopathic pulmonary fibrosis (IPF). 

Scooped by Bill Vick
Scoop.it!

Guideline updates treatments for idiopathic pulmonary fibrosis - #IPF

Guideline updates treatments for idiopathic pulmonary fibrosis - #IPF | Pulmonary Fibrosis News | Scoop.it

Guideline updates treatments for idiopathic pulmonary fibrosis. Unchanged from the 2011 guideline were a conditional recommendation againstN-acetylcysteine monotherapy based on low confidence in effect estimate and a conditional recommendation for antacid therapy based on very low confidence in effect estimate. http://t.co/hshfxk0Tqd

Bill Vick's insight:

The following recommendations are new or revised from the previous guideline:

a strong recommendation against the use of warfarin (low confidence in effect estimates); imatinib (moderate confidence in effect estimates); combination prednisone, azathioprine, and N-acetylcysteine (low confidence in effect estimates); and the selective endothelin receptor antagonist ambrisentan (low confidence in effect estimates),a conditional recommendation for the use of nintedanib (moderate confidence in effect estimates) and pirfenidone (moderate confidence in effect estimates), anda conditional recommendation against the use of the phosphodiesterase-5 inhibitor sildenafil (moderate confidence in effect estimates) or the dual endothelin receptor antagonists macitentan and bosentan (low confidence in effect estimates).
more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

European Patent Office grants patent for treatment of Idiopathic Pulmonary Fibrosis #IPF

The patent reflects the personalized medicine approach in IPF employing also the change of route of administration (now inhalation) by repurposing into IPF of Interferon gamma, that is regulatory approved for treatment of other conditions applied by subcutaneous injection.

Bill Vick's insight:

THERAMetrics holding AG announces today to have been granted by the European Patent Office the patent for a pharmaceutical kit for the targeted treatment of Idiopathic Pulmonary Fibrosis (IPF) by inhalation of Interferon gamma after molecular characterization of the disease. 

more...
No comment yet.
Scooped by Bill Vick
Scoop.it!

Robert Davidson speaks about his experiences with IPF

Robert Davidson founded the Canadian Pulmonary Fibrosis Foundation in 2009 two years after he was diagnosed with Idiopathic Pulmonary Fibrosis (IPF).
more...
No comment yet.